High-Efficacy Therapy Discontinuation vs Continuation in Patients Aged 50 Years or Older With Nonactive MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS
JAMA Neurol 2024 Mar 25;[EPub Ahead of Print], G Jouvenot, G Courbon, M Lefort, F Rollot, R Casey, E Le Page, L Michel, G Edan, J de Seze, L Kremer, K Bigaut, S Vukusic, G Mathey, J Ciron, A Ruet, E Maillart, P Labauge, H Zephir, C Papeix, G Defer, C Lebrun-Frenay, T Moreau, DA Laplaud, E Berger, B Stankoff, P Clavelou, E Thouvenot, O Heinzlef, J Pelletier, A Al-Khedr, O Casez, B Bourre, P Cabre, A Wahab, L Magy, JP Camdessanché, I Doghri, S Moulin, H Ben-Nasr, C Labeyrie, K Hankiewicz, JP Neau, C Pottier, C Nifle, N Collongues, A KerbratFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.